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Abstract 
 
Australia’s policy on Quality Use of Medicines (QUM) aims to achieve appropriate 
use of medicines and improved health outcomes. Drug and Therapeutics 
Committees (DTCs) are educators, policy makers as well as financial gatekeepers 
in matters relating to medicine use. Increasingly, DTCs are also involved in risk 
management and clinical governance. As such, DTCs could be considered to be 
QUM advocates in the institutions in which they function. In a health care arena 
where there are escalating demands on high standards of clinical practice, quality 
assessment and improvement is essential in ensuring safe and effective patient 
care. Given the role DTCs play in safeguarding the interests of the stakeholders of 
the health care system, research into ways in which DTC performance could be 
enhanced is required. 
 
Although indicators specific to DTCs exist, the literature does not seem to provide 
straightforward answers to the question of what is currently being done in terms of 
quality assessment and quality improvement of DTCs. In the absence of such data, 
an opportunity for research is clearly identified. The first aim of this research project 
was to gain insight into the current activities undertaken by, and challenges facing 
Australian DTCs. Following this, the second aim was to explore ways in which DTC 
performance could be augmented. 
 
In addressing the first aim of this project, a national survey of Australian DTCs was 
conducted. These findings reinforce the evidence in the literature about the roles, 
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structure and stakeholder expectations of DTCs. Our research also documents 
DTCs’ quality improvement initiatives and barriers to DTC activities. It appears that 
there is little support available to Australian DTCs. Further, a case study was 
undertaken in order to gain an understanding of the depth and detail of DTC 
operations. An audit of a DTC in an Australian hospital was conducted. This study 
revealed that DTC decisions are being implemented in an ad hoc manner. In fact, 
there were no strategies (or action) planned to implement the majority of their 
decisions. This could have an impact on DTC performance. 
 
In view of this finding, qualitative methods were used to explore stakeholder 
opinions regarding the implementation of DTC decisions and policies. Stakeholders 
believed that strategies used to implement DTC policies should be targeted (to the 
audience as well as the type of decision/policy being implemented), timely, and 
delivered at the point of care. Face-to-face strategies were perceived to be more 
effective than printed materials, particularly when an influence on clinical practice 
was desired. Stakeholders also felt that the lack of resources was a significant 
barrier to DTC performance augmentation. This probably contributed to a lack of 
follow-up (or review) of implemented policies. According to stakeholders, other 
barriers to policy implementation include a lack of ownership of policies, low DTC 
profile, and an over-reliance on pharmacy to implement DTC decisions. 
Stakeholders felt one of the ways in which DTC performance could be improved 
was to prioritise DTC decisions for implementation. 
 
In pursuit of a method to prioritise DTC decisions, a survey was conducted. 
Stakeholders identified patient safety, cost, and the practice of evidence-based 
medicine as domains of important DTC decisions. The results also suggest that 
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stakeholders recognise the need for the prioritisation of DTC decisions for 
implementation. Stakeholders implied that higher priority would be assigned to DTC 
decisions considered to be important. In a follow-up survey, stakeholders (including 
doctors, nurses, pharmacists, and DTC members) seemed to have agreement of 
the primary domains of DTC decisions. Higher levels of importance and higher 
priority were assigned to decisions involving the primary domains of patient safety 
and cost. However, level of importance and priority assignment were not 
consistently correlated.  
 
The work presented in this thesis suggests that there are ways to improve DTC 
performance. Although conducted primarily on hospital-based DTCs, it is 
anticipated that the lessons learnt could be applied to state-based, or even, Area 
Health-based DTCs. In conclusion, this research found that there was a range of 
views regarding “importance” and prioritisation for implementation. Social, 
organisational, as well as environmental factors may contribute to this. Future 
research should examine other possible factors contributing to the importance and 
priority of DTC decisions, so that DTC policy could be appropriately implemented 
into practice.  
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Preface 
 
The work set out in this thesis investigates the little researched area of Drug and 
Therapeutics Committees (DTCs) within the Australian health care setting. Health 
care is concerned with ensuring the safe and efficacious use of medications to treat 
diseases and maintain health. The Australian health care system is considered to 
be among the best in the world.(1) One of the reasons for this may be because 
Australia has a national medicines policy on quality use of medicines. 
 
DTC decisions may influence the types, ways, and amount of medications used in 
hospitals. DTCs play a pivotal role in ensuring value-for-money use of medicines 
within their institutions. Therefore, it could be argued that DTCs contribute to 
achieving rational drug use in their institutions. 
 
Evidence based medicine has become an accepted paradigm for clinical decision 
making.(2, 3) DTCs frequently develop guidelines and policies regarding the use of 
medicines, based on evidence.(4)  However, evidence-based guidelines and 
policies can be undermined if they are disregarded by practitioners and clinicians 
because of inconsistent, inappropriate and ineffective implementation. Evidence-
based decisions need to be followed by evidence-based implementation. Ad hoc 
implementation could also contribute to a considerable gap between knowledge 
and practice. If DTCs are to contribute successfully to achieving quality use of 
medicines, then more needs to be done to ensure that the investment of time, 
expertise, effort and knowledge on DTC decisions is not wasted.  
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This research examines the current challenges facing drug committees in Australia 
and the ways in which DTC outcomes and performance could be improved. It is 
surprising to note that despite the importance of quality use of medicines for health 
outcomes in hospitals, little work has been conducted in this area of research 
previously. 
 
This thesis is divided into three broad sections. In the first section, Chapters 1 and 
2, a literature review is presented. A review of drug use is presented in Chapter 1. 
This includes an overview of the extent of drug use, problems relating to drug use, 
the need for quality in drug use as well as drug use in hospitals. The principles of 
quality use of medicines (QUM) are also outlined in Chapter 1. This review 
underpins the subsequent research in this thesis. In Chapter 2, a review of the 
literature is presented. The published literature relating to DTCs was reviewed with 
the purpose of understanding the representation, structure, roles and function of 
DTCs. 
 
The second section, Chapters 3 and 4, describes two evaluations of DTCs in 
Australia. Chapter 3 reports a national survey of DTCs. This work adds to the 
current “macro-view” of Australian DTCs. This study also explores functions, 
representation, resources (how are Australian DTCs being supported), and 
performance (performance evaluation including influence on prescribing as 
determined by the DTCs). Chapter 4 presents a “micro-view” of a DTC in an 
Australian hospital. In this chapter, an audit of the DTC’s decisions was conducted 
in order to investigate how decisions were being implemented.  
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The third section of this thesis, (Chapters 5 to 7) includes three studies. These 
studies explored strategies to improve DTC performance. Qualitative and 
quantitative methodologies were employed. A consistent theme from the results (in 
Chapters 3, 4 and 5) was that DTCs were functioning with scarce resources. This 
lack of resource has significant consequences on the implementation and follow-up 
of DTC decisions. A novel approach to decision implementation needed to be 
explored. However, there is an absence of information in the public domain as to 
what could be done. 
 
In light of this, the prioritisation of DTC decisions for implementation was explored. 
This is described in the last section of the thesis. A chosen approach (based on the 
findings in Chapter 5) was to assign higher priority to those decisions which were 
considered more important. Chapter 6 details a survey of stakeholders undertaken 
to identify what were the criteria (or domains) used to determine important 
decisions.  In Chapter 7, priority setting based on these “criteria of importance” was 
explored. Stakeholders’ identification of the primary criteria (or domains) relating to 
DTC decisions was investigated. In this study, stakeholders’ assignment of priority 
to decisions which they considered important was also examined. 
 
The final chapter (Chapter 8) summarises major findings and draws some general 
conclusions and implications of this work. 
 
Currently, DTCs function in an environment where much is expected of them, yet 
little is invested in them. It appears decisions are implemented, at best, in a 
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piecemeal fashion. The results of this work raise important issues concerning the 
ways in which DTCs function, as unimplemented decisions may diminish the 
possibility for quality use of medicines. 
